|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Lawson Health Research Institute |
|---|---|
| Information provided by: | Lawson Health Research Institute |
| ClinicalTrials.gov Identifier: | NCT00216814 |
Purpose
To determine if there is an association between basic fibroblast growth factor,vascular endothelial growth factor, and interleukin levels and a patients response to BCG treatment ( as standard treatment)in the urine of patients with superficial TCC. To determine if the levels of these angiogenic factors can predict response to BCG, disease recurrence, progression risk factors.
| Condition |
|---|
|
Bladder Cancer |
| Study Type: | Observational |
| Study Design: | Cohort, Prospective |
| Official Title: | Intravesically Administered BCG May Have Antiangiogenic Effects on Urinary Concentrations of Basic Fibroblast Growth Factor ( bFGF), Vascular Endothelial Growth Factor (VEGF) and Interleukin (IL-8) |
| Enrollment: | 220 |
| Study Start Date: | October 2003 |
| Study Completion Date: | September 2007 |
200 patients that are candidates for intravesical BCG therapy and 20 control patients with no history of malignancy will be enrolled. The study group wol;; be asked to provide a urine sample just prior to receiving their first BCG treatment(week # 1) and just prior to receiving their last (week # 6) BCG treatment. The control patients will provide one urine sample only. Samples will be analysed by enzyme-linked immunosorbant assay(ELISA). clinical data will be reviewed on tumor stage and grade prior to BCG, timme to recurrence, tumor stage and grade of recurrence, time to disease progression and death, cause of death and total follow-up time.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Patients with bladder cancer that are receiving treatment with BCG.
Inclusion Criteria:
200 study group 1. Must be a candidate for BCG therapy. 20 control group 1. No history of malignancy.
Exclusion Criteria:
Contacts and Locations| Canada, Ontario | |
| London Health Sciences Centre | |
| London, Ontario, Canada, N6A 4G5 | |
| Principal Investigator: | Jonathan Izawa, MD, FRCSC | LHRI |
| Principal Investigator: | Jonathan Izawa, MD, FRCSC | LHRI |
More Information
| Study ID Numbers: | R-03-275, 10050E |
| Study First Received: | September 19, 2005 |
| Last Updated: | April 18, 2008 |
| ClinicalTrials.gov Identifier: | NCT00216814 |
| Health Authority: | Canada: Health Canada |
|
antiangiogenic effects of bcg treatment and prognosis |
|
Cystocele Urologic Diseases Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Neoplasms |
Endothelial Growth Factors Urologic Neoplasms Urinary tract neoplasm Bladder neoplasm |
|
Neoplasms Neoplasms by Site |
